TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04097184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation with non-implanted electrodes
Description: Neurostimulation with non-implanted electrodes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostimulation with non-implanted electrodes
Description: Neurostimulation with non-implanted electrodes
Study: NCT06369051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-employment support intervention
Description: A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
Study: NCT05942989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki implementation
Description: Reiki is implied by putting hands on the patient and it is believed that energy is transferred to patients by hands.
Study: NCT05823077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bergamot
Description: The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
Study: NCT05961384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat
Description: a blood pressure lowering drug, oral dose
Study: NCT05365464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Pill
Description: Orally active progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Given by subcutaneous injection
Study: NCT05611424

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.
Study: NCT05290974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self exploring of available online material on supraclavicular brachial plexus block
Description: Potential new method of learning a specific regional anesthesia technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in-person teaching on supraclavicular brachial plexus block
Description: Conventional method of learning a specific regional anesthesia technique
Study: NCT06092983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10383
Description: HS-10383 administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10383 Placebo
Description: HS-10383 Placebo administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
Study: NCT05617547

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse Oximeter (Massimo)
Description: The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
Study: NCT05040490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex as reversal drugs
Description: use sugammadex to reverse neuromuscular blockade
Study: NCT05975866

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Daily consumption of three 500 mg curcumin capsules with breakfast, lunch, and dinner
Study: NCT05808127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainTracker
Description: The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
Study: NCT01637571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexilant
Description: 60mg of Dexilant QD for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexilant Placebo
Description: 60mg of Dexilant placebo QD for 12 weeks
Study: NCT05344274

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Angiography
Description: Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isocapnic Oxygen
Description: Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Description: Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
Study: NCT05649202

Intervention type: OTHER
Intervention: Xpert® HCV Viral test
Description: an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.

Intervention type: OTHER
Intervention: FibroScan® test
Description: A non invasive test made on a small area of skin coated with a gel
Study: NCT04817800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)
Description: It will be nasaly administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)
Description: It will be nasaly administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)
Description: It will be nasaly administered
Study: NCT05243329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 10 mg or 25 mg oral aqueous psilocybin solution
Study: NCT06035549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Digital Resilience-Building
Description: The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
Study: NCT05975866

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Anti-inflammatory diet
Description: The anti-inflammatory diet will be personalized based on each person's calorie intake in five meals. Achieving the goals of an anti-inflammatory diet by consuming only one type of food or following its principles in one meal is impossible and must be implemented consistently and regularly in a meal plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Description: The anti-inflammatory diet will be personalized based on each person's calorie intake in five meals. Achieving the goals of an anti-inflammatory diet by consuming only one type of food or following its principles in one meal is impossible and must be implemented consistently and regularly in a meal plan.
Study: NCT05625971

Intervention type: OTHER
Intervention: MRD Assessment
Description: MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
Study: NCT05511844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-5029
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-5029
Description: Intravenous infusion
Study: NCT04842890

Intervention type: RADIATION
Group type: OTHER
Intervention: Pencil Beam Scanning Proton SBRT
Description: The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
Study: NCT05013229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IcoSema
Description: Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
Study: NCT06038032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital wellness platform
Description: A digital wellness platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online healthcare professional support
Description: Individual sessions with a registered dietitian, an exercise professional, and a mental health therapist for 16 weeks.
Study: NCT06289881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafill-Test product
Description: Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafill-Reference product
Description: Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
Study: NCT05198362

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tesomet
Description: Fixed-dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet
Description: Fixed-dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet
Description: Fixed-dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesomet
Description: Fixed-dose combination
Study: NCT06569264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using autogenous demineralized dentin graft and i-PRF
Description: Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. Followed by inspection of extraction socket integrity, using a William's graduated periodontal probe. Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries or restorations using a high-speed fine finishing stone and saline irrigation. The pulp chamber will be cleaned with sterile endodontic files. Teeth will be ground, using hand bone mill.The (ADDG) particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralized then washed twice in saline and dried with sterile gauze. For i-PRF blood will be withdrawn in plastic tubes. The tube will be centrifuged at around 700 RPM for 3 minutes, and extraction socket will be filled with the graft material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using vitamin C with dentin graft and i-PRF
Description: Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. 25mM of pure vitamin C in Fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes. Extraction socket will be filled with the corresponding graft material and the dentin graft.
Study: NCT04619082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide 25 mg once per day for one year
Study: NCT05178979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
Study: NCT06162234

Intervention type: OTHER
Intervention: observational
Description: none (observational study)
Study: NCT06367270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pressured Intraperitoneal Aerosol Chemotherapy
Description: PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.
Study: NCT05447247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncturing Ba Liao point under ultrasound guidance
Description: Acupuncturing Ba Liao point under ultrasound guidance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncturing Ba Liao point under ultrasound guidance
Description: Acupuncturing Ba Liao point under ultrasound guidance
Study: NCT06494982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
Description: Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
Description: Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
Study: NCT05467150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
Study: NCT06082544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini-screw implant
Description: JEIL SCREW 1.6\* 8 MM 16-G2-008 or JEIL SCREW 1.6\*10 MM 14-G2-010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini-screw implant
Description: JEIL SCREW 1.6\* 8 MM 16-G2-008 or JEIL SCREW 1.6\*10 MM 14-G2-010
Study: NCT05185128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS social skills intervention
Description: The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Among others, this parent-assisted, social skills intervention provides explicit instruction to target verbal and nonverbal communication skills, appropriate use of humor and resolving peer conflict, as well as expanding and developing friendship networks38. The candidate, Dr. Nair, has been trained on the PEERS social skills intervention extensively for the past five years, and is a certified provider for the adolescent program. The PEERS program will be provided by Dr. Nair's research team (consisting of Dr. Nair, lab co-ordinators, and clinical psychology doctoral students) through the LLU Department of Psychology.
Study: NCT06082544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable partial denture
Description: Acrylic removable partial denture
Study: NCT06408298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 400Mg Tab
Description: hydroxychloroquine sulfate tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablet
Study: NCT06363955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbamide Peroxide Mouthwash
Description: The experinmental mouthwah is a solution containing 4.3% w/v hydrogen carbamide, which breaks down to 1.51% w/v hydrogen peroxide, serving as the active ingredient. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine. It is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Placebo mouthwash is a similar (look-and-taste-alike) solution to the experinmental mouthwash made by the same manufacturer, without active ingredients. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine.
Study: NCT06555783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680
Description: Oral tablet containing ALKS 2680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680
Description: Oral tablet containing ALKS 2680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680
Description: Oral tablet containing ALKS 2680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet containing placebo for once daily administration
Study: NCT00917982

Intervention type: OTHER
Group type: OTHER
Intervention: vision therapy
Study: NCT04867330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toxicities reduced treatment arm
Description: Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
Study: NCT05877196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT)
Description: Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
Study: NCT04983953

Intervention type: DEVICE
Intervention: cHS
Description: Clinical decision support system for diagnosing intracranial haemorrhage

Intervention type: DEVICE
Intervention: cHS
Description: Clinical decision support system for diagnosing intracranial haemorrhage
Study: NCT05877196

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Chair-based Stretch
Description: Stretching while seated for 30-50 minutes, 3 times per week for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Description: Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Aerobic Resistance Exercise (CARE)
Description: 6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
Study: NCT06032416

Intervention type: RADIATION
Group type: OTHER
Intervention: Preoperative CT Scan
Description: Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
Study: NCT05597306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Bomedemstat will be administered orally once daily via capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Bomedemstat will be administered orally once daily via capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally once daily via tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered orally once daily via tablet.
Study: NCT05215600

Intervention type: DEVICE
Intervention: Anaverse Shoulder System
Description: Reverse Shoulder Arthroplasty
Study: NCT06446024

Intervention type: DEVICE
Intervention: Mechanical aspiration thrombectomy
Description: Mechanical thrombectomy is an endovascular technique for removing blood clots from vessels. Penumbra's Indigo system actively extracts thrombus using a continuous vacuum pump, enabling aspiration of thrombus of various sizes and lengths.
Study: NCT05958407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: After a loading dose of 600 mg under the skin (s.c.) at baseline, trial participants are administered a dose of 300 mg every two weeks for 32 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks
Study: NCT05742776

Intervention type: OTHER
Intervention: Assessment of Sleep Quality
Description: Assessment of Sleep Quality

Intervention type: OTHER
Intervention: Assessment of Sleep Quality
Description: Assessment of Sleep Quality